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Background: Antithrombotic treatment is a continuous therapy that is often performed in general practice and
requires careful safety management. The aim of this study is to investigate whether a best-practice model that
applies major elements of case management and patient education, can improve antithrombotic management in
primary healthcare in terms of reducing major thromboembolic and bleeding events.
Methods: This 24-month cluster-randomized trial will be performed with 690 adult patients from 46 practices. The
trial intervention will be a complex intervention involving general practitioners, healthcare assistants, and patients
with an indication for oral anticoagulation. To assess adherence to medication and symptoms in patients, as well as
to detect complications early, healthcare assistants will be trained in case management and will use the
Coagulation-Monitoring List (Co-MoL) to regularly monitor patients. Patients will receive information (leaflets and a
video), treatment monitoring via the Co-MoL and be motivated to perform self-management. Patients in the
control group will continue to receive treatment as usual from their general practitioners. The primary endpoint is
the combined endpoint of all thromboembolic events requiring hospitalization and all major bleeding
complications. Secondary endpoints are mortality, hospitalization, strokes, major bleeding and thromboembolic
complications, severe treatment interactions, the number of adverse events, quality of anticoagulation, health-
related quality of life, and costs. Further secondary objectives will be investigated to explain the mechanism by
which the intervention is effective: patients’ assessment of chronic illness care, self-reported adherence to
medication, general practitioners’ and healthcare assistants’ knowledge, and patients’ knowledge and satisfaction
with shared decision making.
Practice recruitment is expected to take place between July and December 2012. Recruitment of eligible patients
will start in July 2012. Assessment will occur at three time points: baseline and follow-up after 12 months and after
24 months.
Discussion: The efficacy and effectiveness of individual elements of the intervention, such as antithrombotic
interventions, self-management concepts in orally anticoagulated patients, and the methodological tool of case
management, have already been extensively demonstrated. This project foresees the combination of several proven
instruments, as a result of which we expect to profit from a reduction in the major complications associated with
antithrombotic treatment.
Trial registration: Current Controlled Trials ISRCTN41847489
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Oral anticoagulation has been shown to be highly effect-
ive in preventing thromboembolic complications in
patients for whom it is indicated [1,2]. Atrial fibrillation,
the incidence of which increases with age and approaches
10% for individuals aged ≥80 years, carries the major risk
of a stroke [3,4]. In Germany, large-scale epidemiological
data are unavailable, hence it can only be estimated that
about 1 million people are suffering from atrial fibrillation.
The German Competence NETwork on Atrial Fibrillation
(AFNET) has initiated a large nationwide patient registry
to evaluate the current daily care of patients with atrial
fibrillation in Germany [5]. The registry shows that antic-
oagulation for stroke prevention was given to 71% of
patients considered eligible according to applicable guide-
lines and to 48.4% of low-risk patients, for whom guide-
lines do not recommend anticoagulation, meaning that
overtreatment may also exist. In an international study
that also included German patients, it was reported that
only about 65% of patients requiring treatment and not
presenting any contra-indications received anticoagulation
treatment [6]. In addition, due to relatively narrow thera-
peutic ranges, it is often only a small percentage of inter-
national normalized ratio (INR) values that are found to
be within the target range. This proportion, as German
studies of patients receiving routine care have shown, can
be as low as <40% of INR measurements [7,8]. As it is well
known that about 44% of bleedings occur when INRs are
above the therapeutic range, that about 50% of thrombo-
embolic events happen when INR values are too low [9],
and that improved oral anticoagulation is an indirect par-
ameter for the reduced incidence of thromboembolic
and hemorrhagic events, there is a real need to im-
prove anticoagulation control. Furthermore, our own
analysis of the oral anticoagulation therapy treatment
process in 16 general practices in Germany identified
safety gaps. These were mainly found in documenta-
tion, patient participation, knowledge of side effects,
and interactions [10].
The new oral agents dabigatran, a direct thrombin in-
hibitor, and rivaroxaban, a direct Factor Xa inhibitor,
have recently been approved for patients with a long-
term indication for antithrombotic treatment. Dabigatran
has been approved for patients with nonvalvular atrial
fibrillation and one additional risk factor for stroke, with
approval primarily based on the results of the RE-LY
study [11]. Compared to warfarin, dabigatran adminis-
tered at a dose of 150 mg was associated with lower rates
of stroke and systemic embolism but similar rates of
major bleedings. However, in November, the European
Medicines Agency (EMA) updated the safety label for
dabigatran after reports of several cases of fatal bleeding
events in patients of relatively high age that had renal in-
sufficiency and low body weight [12]. Rivaroxaban wasapproved in December 2011 for two long-term indica-
tions (patients with nonvalvular atrial fibrillation and one
additional risk factor for stroke and to prevent the re-
occurrence of deep venous thrombosis and pulmonary
embolism). With regard to atrial fibrilliation, data pri-
marily based on the ROCKET-AF study could not show
superiority versus warfarin in terms of a reduction in the
incidence of strokes, systemic embolisms, or major bleed-
ing complications [13]. However, as both new oral agents
have recently been approved, special caution relating to
drug interactions, renal insufficiency, and low body
weight (as with dabigatran) is required because unknown
risks may exist in an unselected patient population [14].
The efficacy and effectiveness of antithrombotic treat-
ment have already been extensively demonstrated. How-
ever, no study has yet analyzed a complex intervention
that incorporates further elements of proven benefit,
such as self-management of OAC patients and case man-
agement in general practices. Systematic reviews [15-17]
and a randomized controlled trial (RCT) in elderly
patients [18] have confirmed that thromboembolic events
and deaths can be reduced in patients performing self-
management, with no difference in the incidence of
major hemorrhagic complications. In the long-term RCT
of elderly patients, self-management of OAC was able to
improve general treatment satisfaction, as well as having
a positive effect on treatment-related quality of life [19].
Case management is generally defined as a clinical, edu-
cative, and social service provided to individuals with
high needs [20]. It mostly includes planned services for
coordinating care, systematic follow-up, and evidence-
based guidelines. Beneficial effects of case management
in primary care have been shown—partially based on our
own results—for many chronic diseases (e.g., diabetes
[21], depression [22,23], chronic heart failure, osteoarth-
ritis [24] and other diseases, as well as continuous ther-
apies [25]). As it is proactive and patient oriented, case
management can be expected to increase adherence to
antithrombotic therapy and, therefore, improve quality of
care.
The aim of this study is, therefore, to improve antith-
rombotic management in primary healthcare by applying
major elements of case management, including patient
education, and to test their effectiveness in terms of re-
ducing major thromboembolic and bleeding events.
Methods/design
Study design
Primary care management for optimized antithrombotic
treatment (PICANT) is to be a cluster RCT with the
general practice as the unit of randomization (see Figure 1).
Since healthcare assistants (HCAs) and general practi-
tioners (GPs) trained in the intervention will not be
in a position to provide care as usual, a clustered design




















Figure 1 Description of schedule and expected duration of the PICANT trial.
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was chosen in order to reduce treatment group contamin-
ation. Practices will be randomly allocated to the case man-
agement or usual care arm in a ratio of 1:1. Practice
allocation to treatment groups will be performed using the
web-based randomization tool “Randomizer for Clinical
Trials,” developed by the Institute for Medical Informatics,
Statistics and Documentation, Medical University of Graz
(www.randomizer.at). After patient recruitment and base-
line assessment have been completed in a practice, a mem-
ber of the Institute of General Practice will use the
web-based randomization tool to obtain information
on the allocated treatment group. Allocation conceal-
ment will take place after completion of the baseline
documentation for all study patients from a specific
practice, but before the intervention begins.Practice and patient recruitment
The trial will be primarily conducted in general practices
in the state of Hesse, Germany.
Practices are eligible for the trial if they provide health
services to persons with German statutory health insur-
ance and have a software system at their disposal that is
capable of detecting potentially eligible patients.
Practices already participating in studies aimed at im-
proving quality of oral anticoagulation will be excluded.
Participating GPs must sign an informed consent form
and agree to implement the study protocol. Potentially
eligible practices will be identified by means of an ad-
dress database provided by the Association of Statutory
Health Insurance Physicians of Hesse. The practices will
be stratified according to the number of inhabitants of
the postal area in which the practice is located. Based on
our own recruitment experience during previous studies
involving general practices in Hesse [26], we would ex-
pect to have to contact >500 practices to recruit the
required number of practices for the trial. In a first step,
we will write a formal letter inviting approximately 500
randomly selected practices to participate in the study. Ifthe required number of participating practices is not
achieved, further randomly selected practices (in steps of
250 practices at a time) will be contacted and asked to
participate. The random samples will be selected by
means of the random number generator function in
Microsoft ExcelW (Microsoft Corporation, Redmond, WA,
USA). The random selection of practices will be per-
formed by a member of the study team in the presence of
a third person who is not involved in the study.
Each participating practice will be asked to create a
screening list of potentially eligible patients by means of
their software and on the basis of predefined instructions.
At the first practice visit, the GP will go through the
screening list in the presence of a member of the study
team and assess the inclusion and exclusion criteria of the
patients until 30 eligible patients have been identified. To
avoid a selection bias, the order of the patients assessed
for eligibility will be randomly chosen by means of the
random number generator function in Microsoft Excel.
The 30 eligible patients will then receive a written invita-
tion from the GP to participate in the study. Once 15
patients have been included, patient recruitment will be
ceased. This recruitment strategy was developed in ac-
cordance with previous studies [26,27]. The process used
to identify eligible study patients was pilot tested in seven
practices and found to be feasible.Inclusion and exclusion criteria for patients
Adult patients of ≥18 years of age and with a long-term
indication for oral anticoagulation (atrial fibrillation/
flutter, recurrent venous thromboembolism or pulmon-
ary embolism, mechanical heart prosthesis, and others,
such as hereditary coagulopathy, intracardial throm-
bosis) and an indication for coumarins, antiplatelet ther-
apies, or the new antithrombotic agents rivaroxaban and
dabigatran will be included in the study. They should
regularly attend the GP’s practice and must sign an
informed consent form. Exclusion criteria for patients
are dementia, diseases resulting in a life expectancy of
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auditory defects, alcohol or drug abuse, residence in
institutions (e.g., nursing homes or residential care
homes) that do not allow study participation, and a lack
of German language skills.
Outcome measures
The primary patient-relevant endpoint of the trial is the
combined endpoint of all thromboembolic events requiring
hospitalization and all major bleeding complications, as
assessed by the GP and documented in the case report
form. Major bleeds include (1) fatal bleeding; (2) symptom-
atic bleeding in a critical area or organ, such as intracranial,
intraspinal, intraocular, retroperitoneal, intraarticular
or pericardial, or intramuscular with compartment
syndrome; and/or (3) bleeding causing a fall in the
hemoglobin level of 20 g/L (1.24 mmol L-1) or more
or leading to the transfusion of two units of packed
red blood cells [28]. Thromboembolic events requir-
ing hospitalization include arterial embolism (stroke,
transient ischemic attack, myocardial infarction, per-
ipheral arterial embolism), venous thromboembolism
(e.g., deep venous thrombosis, pulmonary embolism),
and valve thrombosis [18,29].
The following key secondary endpoint(s) will be evalu-
ated by means of the case report forms (filled in by the
GPs) and patient questionnaires: all-cause and cause-
related mortality rates, frequency and duration of
hospitalization, number of recurrent strokes (ischemic
and hemorrhagic stroke), major bleeding and thrombo-
embolic complications (as defined for the primary end-
point), the number of patients with at least one
potentially severe treatment interaction, total number of
potentially severe treatment interactions involving oral
anticoagulants, the number of adverse events, quality of
anticoagulation (e.g., time within therapeutic range) [30],
health-related quality of life (EQ-5D) [31], and costs.
Further secondary objectives will be investigated to ex-
plain the mechanism by which the intervention is effect-
ive: patients’ assessment of chronic illness care (PACIC)
[32], self-reported adherence to medication (Morisky
Questionnaire) [33], general practitioners’ and healthcare
assistants’ knowledge (self-developed knowledge ques-
tionnaire), patients’ knowledge (questionnaire developed
by Hua) [34], and satisfaction with shared decision mak-
ing (Man-Song Hing test) [35].
All primary and secondary outcomes will be measured
at patient level at baseline (T0) and at follow-ups at 12
months after baseline (T1) and 24 months after baseline
(T2). All events will be documented in case report forms
and cross-checked by reviewing doctors’ reports, dis-
charge letters, and death certificates. Allocation conceal-
ment will take place after completion of the baseline
documentation for all study patients from a specificpractice, but before the intervention begins.We will con-
duct qualitative interviews with patients, HCAs, and GPs
to evaluate the perceptions of and satisfaction with
practice-based case management and to study the general
practitioners’ reasons for changing medication to the new
antithrombotic drugs (dabigatran or rivaroxaban).
Intervention in the treatment groups
At the first practice visit, all practices (before
randomization) will be provided with the current
evidence-based guideline for GPs, “Anticoagulation” of
the Guideline Group of Hesse, as a “recommended
standard” [36] and a standardized information leaflet
(issued by the German Society of General Practice
and Family Medicine) for their patients [37].
Intervention group
Practices randomized to the intervention group will receive
a complex intervention, including the provision of add-
itional tools and guidelines to GPs and their practice teams.
The HCAs will be trained in performing case management
and educating patients (including a patient information
leaflet and a video developed by Hua et al.) [34]. To assess
adherence to medication and symptoms in patients, as well
as detect complications early, HCAs will be trained in case
management and will regularly monitor patients by means
of the Coagulation-Monitoring List (Co-MoL). Practice
routines will be improved. In addition, the GPs will be con-
tacted immediately after randomization and provided with
further explanations of case management by telephone.
Quality circles will be held three times during the course of
the trial (shortly after baseline assessment and after 12 and
24 months) to discuss the practical problems of anticoagu-
lation and individual case reports.
For patients, the intervention will include information
(patient information leaflet and a video developed by
Hua et al. [34]), treatment monitoring via the Co-MoL,
and encouragement to participate in a self-management
course where they will learn how to carry out self-
testing and self-dosing.
Training of the healthcare assistant
At an interactive one-day workshop, one HCA from
each practice assigned to the intervention group will be
trained to perform case management and educate
patients. The main elements of the session will be to in-
form patients about their disease and treatment condi-
tions, to encourage patients to perform self-management
of oral anticoagulation if they are taking coumarins, and
to monitor symptoms and their adherence to antithrom-
botic treatment. HCAs will also be trained to detect com-
plications early and to assess adverse events, such as
major or minor thromboembolisms or bleeding complica-
tions, as well as drug-related side effects and interactions.
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in educating patients willing to perform self-management
will be adapted from the teaching course developed
by Sawicki et al. [8]. For those HCAs who are not
willing to give self-management courses in their
practices, a list of teaching centers where patients
can be transferred will be provided. A model for a
similar course was successfully developed as part of
our Primary Care Monitoring for Depressive Patients
Trial (PRoMPT) study [22].
Control group
For the duration of the trial, the patients in the control
group will continue to receive treatment as usual from
their GP.
Pilot testing
Between November 2011 and March 2012, pilot tests
were conducted in seven practices in order to try out
the process for the identification of eligible patients, as
well as to check the comprehensibility of the instru-
ments. The piloting led to an adaptation of the processes
and questionnaires. The results of the piloting will, how-
ever, not be included in the final analyses.
Sample size calculation
Sample size was calculated by using the primary com-
bined endpoint of all thromboembolic events requiring
hospitalization and all major bleeding complications in
the 24-month intervention period.
Based on data from previously published studies
[11,18,38], we anticipate an event rate of 15% over the
24-month period in the routine-care group. A 50% re-
duction in thromboembolic events and major bleedings
is expected in the case-management group. To detect a
50% reduction between the two treatment groups using
a chi-square test with a two-sided significance level of
5% and a power of 80%, a sample size of 278 patients
per group is needed. To account for the design effect in
this cluster RCT, the sample size will have to be inflated
by the design effect (DE), where DE = 1 + (m − 1)
ICC (m is the average cluster size and ICC is the intra-
class correlation coefficient). In accordance with Campbell
et al., 2007, and Campbell 2000 we will use an estimate of
0.01 for the ICC [39,40]. On the assumption that it will be
possible to identify about 30 eligible patients in each gen-
eral practice and that 50% of these can be recruited for
the study, the adjusted sample size per group is 317. To
account for drop outs and incomplete follow-up, our ob-
jective is to include 345 patients (23 general practices)
per group. In addition, we will include a further four
practices in each group in order to be prepared for any
practice loss. The sample size calculation was performedusing nQuery Advisor 7.0 (Statistical Solutions Ltd., Cork,
Ireland).
Statistical hypotheses, methods, and analyses
The primary analysis of all target criteria will be performed
for all randomized practices and participating patients in
accordance with the intention-to-treat (ITT) principle. The
first event that occurs in a patient will be used for analysis.
A modified ITT analysis with patients switching to the new
antithrombotic treatment (rivaroxaban and dabigatran),
censored at the time of switching, will be performed if it is
applicable. The primary endpoint will be analyzed using an
extended Cox proportional hazards model to take the
effects of clustering into account. A p value of less than 5%
will be considered significant. To assess bias due to missing
data, we will perform sensitivity analyses. Detailed explora-
tory analysis of all secondary endpoints will be conducted.
Subgroup analyses for gender are planned. The statistician
will be blinded with regard to treatment allocation. For stat-
istical analysis, SAS 9.2 (SAS Institute, Inc., Cary, NC,
USA) and SPSS version 19 (IBM, Armonk, NY, USA) will
be used. A detailed description of the statistical methods
used in this study will be provided in a statistical analysis
plan (SAP), which will be finished before database lock.
Ethics and legal aspects
The project will be carried out in conformation with the
Medical Association’s code of conduct and good clinical
practice (GCP) in line with the World Medical Association
Declaration of Helsinki [41]. The trial was checked and
approved prior to the start of the study by the ethics com-
mittee of Frankfurt University Hospital (ethics committee
approval obtained on June 26th, 2011). The study is regis-
tered at www.controlled-trials.com (ISRCTN41847489).
Timeframe of the study
Practice recruitment is expected to take place be-
tween July 2012 and December 2012 (see Figure 1).
Recruitment of eligible patients and baseline data col-
lection will start in July 2012. After cluster randomization,
teams in intervention practices will be consecutively
trained between August and December 2012, prior to
the beginning of the intervention. Data collection for
the 12-month assessment is scheduled from June
2013 to January 2014 and from June 2014 to January
2015 for the 24-month assessment.
Discussion
Antithrombotic treatment is a continuous therapy that is
often performed in general practice. Therapy with cou-
marins, which have a narrow therapeutic range, bears a
considerable risk of adverse thromboembolic and bleeding
events, particularly in the case of dose deviations when
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antithrombotic treatments—who will be included in
the study as well—also require careful safety manage-
ment, and this will continue to be a challenging task
in certain risk populations [14]. According to the
Institute for Safe Medication Practices, coumarins are
one of the five highest-risk medications that are in
wide use, and their utilization can lead to severe or
even lethal adverse events [42].
This cluster RCT compares a best-practice model in-
volving HCAs trained to provide case management with
usual care under “real-world conditions.” HCAs have in-
creasingly been recognized as an underexploited re-
source in chronic care. The model is a complex
intervention, but the effectiveness of all major compo-
nents has been proven. Only the reliable and safe man-
agement of antithrombotic treatment will increase its
use as it would result in increased treatment certainty
among treating doctors and beneficial consequences in
the population at risk. Immediate consequences in terms
of risk reduction (particularly of stroke prevention) will
occur, if the case-management components of the pro-
gram are as effective as expected.
Case management by HCAs will require more
resources within the general practice compared to usual
care, but this will likely be offset by the overall benefits.
In addition to the medical effects in terms of benefits
and harm, economic effects will also be evaluated and
resource consumption will be documented and moni-
tored (risk–benefit assessment).
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